Business Segments · Restructuring Charges
North American Pharmaceutical — Restructuring Charges
McKesson North American Pharmaceutical — Restructuring Charges remained flat by 0.0% to $6M in Q4 2026 compared to the prior quarter. Year-over-year, this metric grew by 500.0%, from $1M to $6M. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityVolatile
First reportedQ3 2016
Last reportedQ4 2026May 8, 2026
Rolls up toRestructuring Charges
How to read this metric
High charges indicate significant organizational change, which may lead to future efficiency gains but represents immediate earnings pressure.
Detailed definition
This metric aggregates all costs associated with formal restructuring programs within the North American Pharmaceutical...
Peer comparison
A standard line item for companies undergoing operational transformation or integration of acquisitions.
Metric ID:
mck_segment_north_american_pharmaceutical_restructuring_chargesHistorical Data
8 periods
| Q3 '24 | Q4 '24 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 | |
|---|---|---|---|---|---|---|---|---|
| Value | $63M | $2M | $6M | $1M | $6M | $6M | $6M | $6M |
| QoQ Change | — | -96.8% | +200.0% | -83.3% | +500.0% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | -90.5% | -50.0% | — | — | +0.0% | +500.0% |
Range$1M – $63M
CAGR-73.9%
Avg YoY Growth+89.9%
Median YoY Growth-25.0%
Current Streak4 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's north american pharmaceutical — restructuring charges?
- McKesson (MCK) reported north american pharmaceutical — restructuring charges of $6M in Q4 2026.
- How has McKesson's north american pharmaceutical — restructuring charges changed year-over-year?
- McKesson's north american pharmaceutical — restructuring charges increased by 500.0% year-over-year, from $1M to $6M.
- What does north american pharmaceutical — restructuring charges mean?
- The total financial cost of executing restructuring initiatives within the North American Pharmaceutical segment.